Abstract
Menopausal symptoms are a common consequence of systemic therapy for breast cancer and can significantly impact on quality of life as well as affect treatment compliance. The most effective treatments available using exogenous hormones are generally cautioned against in women with a history of breast cancer and management of such symptoms can therefore pose a challenge to the health care professional. This chapter focuses on the current options for the treatment of vasomotor and urogenital symptoms in women who have had treatment for breast cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cancer Research UK (CRUK, 2011). www.cancerresearchuk.org/cancerstats/types/breast/incidence. Accessed 1 Oct 2015.
Anderson DJ, Yates P, McCarthy N, Porter-Steele J. Younger and older womens concerns about menopause after breast cancer. Eur J Cancer Care. 2011;2:285–94.
Blaes AH, Kreitzer MJ, Torkelson C, Haddad T. Nonpharmacologic complementary therapies in symptom management for breast cancer survivors. Semin Oncol. 2011;38:394–402.
Carpenter JS, Andrykowski MA, Cordova M, et al. Hot Flashes in postmenopausal women treated for breast carcinoma. Prevelence, severity, correlates, management, and relation to quality of Life. Cancer. 1998;82:1682–91.
Harris PF, Remington PL, Trentham-Dietz A, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;23:501–9.
Dennerstein L, Dudley EC, Hooper JL, et al. A prospective population based study of menopausal symptoms. Obstet Gynecol. 2000;96:351–8.
Kronenberg F. Hot Flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52–86.
Mom CH, Buijs C, Willemse PHB, et al. Hot flushes in breast cancer patients. Critical Reviews Oncology/Haematology. 2006;57:63–77.
Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24:583–90.
Stearns V, Ullmer L, Lopez L, et al. Hot flushes. Lancet. 2002;360:1851–61.
Rosenberg J, Holst-Larsen S. Hypothesis: pathogenesis of postmenopausal hot flushes. Med Hypotheses. 1991;35:349–50.
Neves-e-Castro M, Birkhauser M, Samsioe G G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81:88–92.
Anderson D, Seib C, McGuire A, Porter-Steele J. Decreasing menopausal symptoms in women undertaking a web-based multimodal lifestyle intervention: The Women’s Wellness Program. Maturitas. 2015;81:69–75.
Schover LR, Jenkins R, Sui D, et al. Randomised trial of peer counselling on reproductive health in African American breast cancer survivors. J Clin Oncol. 2006;24:1620–6.
Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014;50:346–58.
Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas. 2010;66:333–43.
Ladycare USA. 2015. http://www.ladycareusa.com/faqs. Accessed 27 Oct 2015.
Royal College of Obstetricians and Gynaecologists. Alternatives to hormone replacement therapy for the management of symptoms of the menopause. 2010. 2010 Scientific Impact Paper No 6 September RCOG.
Royal College of Nursing (RCN). Menopause: lifestyle and therapeutic approaches. RCN guide for nurses, midwives and health visitors. London: RCN; 2014.
Garcia MK, Graham-Getty L, Haddad R, et al. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 2015;121:3948–58.
Smith RL, Flaws JA, Gallicchio L. Does quitting smoking decrease the risk of hot flashes? A longitudinal analysis. Maturitas. 2015;82:123–7.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–27.
Holmberg L, Iversen OE, Rudenstem CM. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475–82.
Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475–8.
Kenemans P, Bundred NJ, Foldart J, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptom: a double-blind, randomized, non-inferiority trial. Lancet Oncol. 2009;10:135–46.
Bertelli G, Venturini N, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol. 2002;13:883–8.
Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006;24:1409–14.
Mohammed H, Russell JA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523:313–7.
Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. J Am Med Asso. 2006;295:2057–71.
Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27:2831–7.
Berhan Y, Berhan A. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptom? A meta-analysis and meta-regression of randomized double-blind controlled studies. Ethiop J Health Sci. 2014;24:209–18.
Barton DL, LaVasseur BI, Sloan JA, et al. Phase III placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG Trial N05C9. J Clin Oncol. 2010;28:3278–83.
Stearns V, Beebe KL, Ivengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289:2827–34.
Johnson JA, Hamadeh IS, Langaee TY. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies. J Natl Cancer Inst. 2015;107:dju437.
Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30–9.
Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther. 2009;31:221–35.
Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28:5147–52.
Loprinzi CL, Qin R, Balcueva EP, et al. Phase III randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28:641–7.
Walaga DR, Rubin LH, Banuvar S, et al. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomised clinical trial in postmenopausal women. Menopause. 2014;21:807–14.
Crandall C, Petersen MS, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004;11:519–30.
Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in ATAC (“Arimidex”, tamoxifen, alone or in combinations) trial after completion of 5 years adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273–84.
Pagani O, Regan MM, Francis PA, et al. International Breast Cancer Study Group. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:1358–9.
Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.
Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two randomised phase 3 trials. Lancet Oncol. 2015;16:848–58.
Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.
Weigerink MA, Poortman J, Agema AR, Thijssen JH. Estrogen receptors in human vaginal tissue. Maturitas. 1980;2:59–67.
Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141:817–20.
Roy S, Caillouette JC, Roy T, et al. Am J Obstet Gynecol. 2004;190:1272–7.
Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in postmenopausal women. The importance of sexual activity and hormones. JAMA. 1983;249:2195–8.
Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–63.
Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril. 1994;61:178–80.
Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15:969–73.
Goetsch MF, Lim JY, AB C. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33:3394–400.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2003;(4):CD001500.
Nilsson K, Helmer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency- a pharmacokinetic and pharmacodynamics study. Maturitas. 1992;15:121–7.
Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:555–62.
Will S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptpr modulator. J Oncol Pract. 2012;8:144–8.
Simmons CE, Kuchuk I, Freedman OC, et al. Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy? Clin Oncol (R Coll Radiol). 2012;24:e128–9.
Donders G, Bellen G, Neven P, et al. Effects of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis. 2015;34:2023–8.
Cold S, Cold F, Jensen MB, et al. Vaginal estrogens and risk of recurrence or death in women treated for estrogen receptor positive breast cancer. 2015. European Cancer Congress Vienna 25–29 Sept 2015.
Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108:1515–24.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mitchell, H., Armstrong, A.C. (2016). Management of Menopausal Symptoms in Breast Cancer Survivors. In: Ring, A., Parton, M. (eds) Breast Cancer Survivorship. Springer, Cham. https://doi.org/10.1007/978-3-319-41858-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-41858-2_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41856-8
Online ISBN: 978-3-319-41858-2
eBook Packages: MedicineMedicine (R0)